One notable exception to this is lncRNA PCA3, an FDA-approved biomarker (‘PROGENSA PCA3 test’) that has improved the specificity from 47% (PSA levels only) up to a 76% (PCA3 levels) for monitoring disease progression in prostate cancer patients whose PSA levels are elevated in serum after a negative biopsy detection 158. This evidence concerns the gene PCA3 and prostate carcinoma.